These privately borne costs might be overlooked from a solely health service perspective, but they represent a vital component of the economic analysis:
their reduction is likely to be a fundamental determinant of patient compliance,
which in turn would lead to improved glycaemic control and a reduction in the health and financial burden associated with poorly controlled diabetes. For this reason, economic analyses should take the widest possible perspective in order to maximise their value as a basis for healthcare decision-making.